Document ID: chunk:federal_register_of_legislation:F2023L01139:reg:9:p1
Version: federal_register_of_legislation:F2023L01139
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 4854–7848

9               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, soft tissue sarcoma or death from soft tissue sarcoma is connected with the circumstances of a person's relevant service:
(1)          inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) for a cumulative period of at least 500 hours, at least 5 years before the clinical onset of soft tissue sarcoma;
Note: inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) is defined in the Schedule 1 – Dictionary.
(2)          undergoing a course of therapeutic radiation for cancer, where the affected region was in the field of radiation, at least 5 years before the clinical onset of soft tissue sarcoma;
(3)          having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the affected region, at least 5 years before the clinical onset of soft tissue sarcoma;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(4)          for angiosarcoma only, having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the affected region at least 2 years before the clinical onset of soft tissue sarcoma;
Note: cumulative equivalent dose and angiosarcoma are defined in the Schedule 1 - Dictionary.
(5)          for hepatic angiosarcoma only, having received ionising radiation to the liver from internal deposition of thorium dioxide (Thorotrast), at least 5 years before the clinical onset of soft tissue sarcoma;
Note: cumulative equivalent dose and angiosarcoma are defined in the Schedule 1 - Dictionary.
(6)          for hepatic angiosarcoma only, inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride, at least five years before the clinical onset of soft tissue sarcoma;
Note: ppm-years and angiosarcoma are defined in the Schedule 1 - Dictionary.
(7)          being treated with an immunosuppressive drug resulting in substantial suppression of immune responses to prevent transplant rejection before the clinical onset of soft tissue sarcoma;
(8)          for leiomyosarcoma and Epstein Barr virus associated smooth muscle tumours, being infected with human immunodeficiency virus before the clinical onset of soft tissue sarcoma;
(9)          for angiosarcoma only, having persistent chronic lymphoedema of the affected region for at least 6 months before the clinical onset of soft tissue sarcoma;
Note: angiosarcoma is defined in the Schedule 1 - Dictionary.
(10)      for uterine sarcoma only, being obese for a period of at least 5 years within the 20 years before the clinical onset of soft tissue sarcoma;
Note: being obese is defined in the Schedule 1 - Dictionary.
(11)      for angiosarcoma only, having an arteriovenous fistula at the site of the angiosarcoma